Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy – results of a non-interventional observation study

Abstract Background Chemotherapy-induced nausea and vomiting (CINV) belong among the most burdensome side effects in hemato-oncology. Mostly, a combination of ondansetron and dexamethasone is used as antiemetic prophylaxis in pediatric patients undergoing emetogenic chemotherapy. However, dexamethas...

Descripció completa

Dades bibliogràfiques

Autors principals:	Semjon Willier, Karin Melanie Cabanillas Stanchi, Martina von Have, Vera Binder, Franziska Blaeschke, Judith Feucht, Tobias Feuchtinger, Michaela Döring
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2019-11-01
Col·lecció:	BMC Cancer
Matèries:	Fosaprepitant Aprepitant Pediatric patients Emetogenic chemotherapy Chemotherapy-induced nausea and vomiting Ondansetron
Accés en línia:	http://link.springer.com/article/10.1186/s12885-019-6252-6
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!